Teleflex (NYSE: TFX) released study results highlighting benefits of its Titan SGS Stapler compared to traditional multi-fire staplers in robot-assisted sleeve gastrectomy. The retrospective study, published in Obesity Surgery, evaluated 257 patients treated between 2016 and 2023 by a single surgeon.
Key findings:
- Postoperative GERD occurred in 7.1% of patients using the single-fire Titan SGS Stapler versus 26.4% with multi-fire staplers.
- New-onset (de novo) reflux was 1.8% with Titan SGS, compared to 10.9% in the other group.
- Patients using Titan SGS had a slightly shorter hospital stay (2 days vs. 2.2 days).
Dr. Forrest Ringold noted the study supports growing evidence for the perioperative advantages of the Titan SGS Stapler in sleeve gastrectomy.
Teleflex reported Q1 2025 revenues of $700.7 million, down 5% year-over-year, partly due to tariffs. The company also announced plans to split into two publicly traded entities, with one focused on Urology, Acute Care, and OEM businesses.
Follow MEDWIRE.AI for surgical device updates and clinical study insights.
